Detalhe da pesquisa
1.
Genetic Analysis of Circulating Tumour Cells.
Recent Results Cancer Res
; 215: 57-76, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31605223
2.
Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer.
Nature
; 493(7432): 406-10, 2013 Jan 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-23242139
3.
The molecular underpinnings of prostate cancer: impacts on management and pathology practice.
J Pathol
; 241(2): 173-182, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27753448
4.
PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients.
Br J Cancer
; 113(8): 1225-33, 2015 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-26379078
5.
Molecular pathology and prostate cancer therapeutics: from biology to bedside.
J Pathol
; 232(2): 178-84, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24108540
6.
Infiltrating S100A8+ myeloid cells promote metastatic spread of human breast cancer and predict poor clinical outcome.
Breast Cancer Res Treat
; 148(1): 41-59, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25270120
7.
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.
J Pathol
; 229(3): 422-9, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23165508
8.
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial.
Eur J Cancer
; 205: 114103, 2024 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38729054
9.
Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.
J Pathol
; 227(1): 42-52, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22252965
10.
Circulating biomarkers of neuroendocrine prostate cancer: an unmet challenge.
BJU Int
; 119(1): 3-4, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28000989
11.
Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer.
Eur Urol Oncol
; 5(6): 659-667, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35491356
12.
Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer.
Clin Cancer Res
; 28(16): 3509-3525, 2022 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35695870
13.
JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer.
Cancer Res
; 81(4): 1087-1100, 2021 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33822745
14.
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.
Eur Urol
; 79(2): 200-211, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33176972
15.
Sarcomatoid carcinoma of the prostate: ERG fluorescence in-situ hybridization confirms epithelial origin.
Histopathology
; 66(6): 898-901, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25041380
16.
Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial.
JCO Precis Oncol
; 42020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33015526
17.
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.
J Clin Oncol
; 38(27): 3195-3204, 2020 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32568634
18.
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers.
Cancer Discov
; 10(10): 1528-1543, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32532747
19.
Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer.
Eur Urol
; 76(4): 469-478, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31345636
20.
Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency.
Eur Urol
; 75(1): 184-192, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30340782